Drug intelligence / Profile preview

FR260500

Development stage: Unknown
Lead developer: Astellas Pharma
Modality: Small Molecules
Administration: Topical

Overview

FR260500 is a small molecule research compound developed by Fujisawa (now Astellas) for the topical treatment of mild to moderate facial acne vulgaris. Chemically, it is a phosphoric acid diester of ascorbic acid (Vitamin C) and tocopherol (Vitamin E), designed to provide the combined antioxidant benefits of both vitamins in a stable, single-molecule delivery system. The compound targets oxidative stress and lipid peroxidation in the skin, which are key factors in the pathogenesis of acne and sebaceous gland overactivity. It was investigated in Phase II clinical trials as a 1% topical gel formulation.

Other names: ascorbyl tocopheryl phosphateL-ascorbyl DL-alpha-tocopheryl phosphateEPCphosphoric acid ascorbyl tocopheryl diester

Beyond the preview

Go deeper on FR260500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FR260500.

Explore the full profile